Humira

Phase 2Small molecule

Boehringer Ingelheim

Humira is one of 61 small molecule programs targeting Psoriatic Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriatic ArthritisActive, not recruiting

LAMRecruiting

UveitisActive, not recruiting

Psoriatic ArthritisPreclinical

Active, not recruiting

LAMPhase 2

Recruiting

UveitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Psoriatic Arthritis

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

17 2

Trexall

Jazz Pharmaceuticals

Approved

13 3

Bimzelx

UCB

Approved

9 4

Taltz

Eli Lilly

Approved

8 5

Rinvoq

AbbVie

Approved

4 6

Mounjaro

Eli Lilly

Approved

3 7

Arava

Sanofi

Approved

2 8

Azulfidine

Pfizer

Approved

2 9

Ozempic

Novo Nordisk

Approved

1 10

Talzenna

Pfizer

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis7 trials

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Completed·MMomenta Pharmaceuticals, Inc.·Phase 3·NCT02581345·572 enrolled

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03210259·259 enrolled

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis

Completed·BBiocad·Phase 3·NCT02762955·344 enrolled

Show 4 more trials

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Completed·FFresenius Kabi SwissBioSim GmbH·Phase 3·NCT02660580·443 enrolled

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02850965·318 enrolled

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

Completed·AAbbott·Phase 3·NCT00513370·203 enrolled

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·SSamsung Bioepis Co., Ltd.·Phase 4·NCT05510063·371 enrolled

Rheumatoid Arthritis5 trials

A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Completed·LLG Life Sciences·Phase 3·NCT02746380·383 enrolled

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Completed·FFujifilm Kyowa Kirin Biologics Co., Ltd.·Phase 3·NCT02405780·645 enrolled

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Completed·FFujifilm Kyowa Kirin Biologics Co., Ltd.·Phase 3·NCT02260791·728 enrolled

Show 2 more trials

A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Completed·SSamsung Bioepis Co., Ltd.·Phase 3·NCT02167139·544 enrolled

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira

Terminated·AAbbott·Phase 4·NCT00761514·14 enrolled

Efficacy and Safety2 trials

A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira

Completed·BBio-Thera Solutions·Phase 3·NCT04135508·554 enrolled

MYL-1401A Efficacy and Safety Comparability Study to Humira®

Completed·MMylan Inc.·Phase 3·NCT02714322·294 enrolled

Crohn's Disease2 trials

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02871635·147 enrolled

A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)

Terminated· AstraZeneca logo

AstraZeneca·Preclinical·NCT03759288·89 enrolled

Adalimumab2 trials

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

Completed· Pfizer logo

Pfizer·Phase 1·NCT01870986·210 enrolled

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Completed· Novartis logo

Novartis·Phase 3·NCT02016105·465 enrolled

12 more indications

Pyoderma Gangrenosum1 trial

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Withdrawn·WWright State University·Phase 2·NCT00730717

Sarcoidosis1 trial

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

Withdrawn·WWright State University·Phase 2·NCT00731757

Immunogenicity1 trial

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Unknown status·MMabscale, LLC·Phase 3·NCT06005532·494 enrolled

Tics1 trial

Pharmacokinetics and Safety Study of LBAL in Healthy Subjects

Completed·LLG Life Sciences·Phase 1·NCT02206867·116 enrolled

ESS1 trial

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Completed·UUniversity of Illinois at Chicago·Phase 4·NCT02451748·32 enrolled

Genetic Polymorphism1 trial

Evaluation of IL 12B Genetic Polymorphism (rs3213094)

Recruiting·SSouth Valley University·N/A·NCT07128472·40 enrolled

Fasting Conditions1 trial

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

Completed·NNanjing King-Friend Biochemical Pharmaceutical Co., Ltd.·Phase 1·NCT07147257·238 enrolled

Psoriatic Arthritis1 trial

IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients

Completed·SSouth Valley University·N/A·NCT06729463·50 enrolled

Asthma1 trial

A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

Withdrawn·AAbbott·Phase 2·NCT00512863·272 enrolled

Uveitis1 trial

Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital

Unknown status·SSohag University··NCT05683626·40 enrolled

LAM1 trial

Personalized Therapies in Inflammatory Complex Disease

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03651518·32 enrolled

Chronic Plaque Psoriasis1 trial

Characterization of Skin Th17 Transcriptional Profiles in Psoriatic Patients Under Adalimumab Biotherapy

Completed·PPoitiers University Hospital·Phase 2·NCT01872546·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Humira. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Humira compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Humira. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

Humira

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis7 trials

Rheumatoid Arthritis5 trials

Efficacy and Safety2 trials

Crohn's Disease2 trials

Adalimumab2 trials

Pyoderma Gangrenosum1 trial

Sarcoidosis1 trial

Immunogenicity1 trial

Tics1 trial

ESS1 trial

Genetic Polymorphism1 trial

Fasting Conditions1 trial

Psoriatic Arthritis1 trial

Asthma1 trial

Uveitis1 trial

LAM1 trial

Chronic Plaque Psoriasis1 trial

References

Drug Info

Quick Facts

Related News